Electrocore - ECOR STOCK NEWS

electroCore (NASDAQ: ECOR) announced the appointment of Thomas Freeburg as VP, Corporate Controller, effective November 11, 2024. The company's Compensation Committee granted him 5,000 restricted stock units (RSUs) as an inducement for employment under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest equally over three years, with 33% vesting on each anniversary of the grant date, contingent on continued employment. Upon vesting, the RSUs will convert to common stock shares.

electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has scheduled its third quarter 2024 financial results announcement for Wednesday, November 13, 2024, after market close. The company will host a conference call and webcast at 4:30 PM EST for management to discuss results and take questions. Participants can join via phone using dial-in numbers 877-407-8835 (domestic) or +1 201-689-8779 (international) with Conference ID 13744121.

electroCore, a bioelectronic medicine and wellness company, has announced its participation in the LD Micro Main Event XVII on October 29, 2024, at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Dan Goldberger, CEO, will represent the company and be available for one-on-one meetings throughout the day.

The presentation is scheduled for 4:30 p.m. PT and will be accessible via a live audio webcast. Interested attendees can register for the conference or contact investors@electrocore.com to arrange meetings with management. The webcast link for the presentation is https://me24.sequireevents.com/

electroCore, a bioelectronic medicine and wellness company, has announced its participation in three upcoming investor events:

• October 1: One-on-one meetings at the Lytham Partners Virtual Fall Investor Conference
• October 17: Fireside chat with Anthony Vendetti at the Maxim Virtual Healthcare Summit
• October 29: One-on-one meetings and group presentation at the LD Micro Main Event XVII in Los Angeles

The LD Micro event presentation is scheduled for 4:30 p.m. PT. Live webcasts and replays will be available on electroCore's investor relations website. Investors can contact FNK IR to schedule meetings with management. The company's participation is subject to change.

electroCore, a bioelectronic medicine and wellness company, has engaged FNK IR to expand its investor relations program. The company has reported seven consecutive quarters of record revenue and a five-year CAGR of 69%. CEO Dan Goldberger cited strong financial performance, high gross margins, and improving operating leverage as reasons for enhancing their investor relations efforts.

Rob Fink, Managing Partner of FNK IR, highlighted electroCore's rapid growth, efficient operations, and strong sales channels. The engagement aims to broaden awareness of electroCore among relevant investors and drive sustainable shareholder value. The company expects to generate positive cash flow early next year.

electroCore, Inc. (Nasdaq: ECOR) announced promising results from an Air Force Research Laboratories (AFRL) study on the effectiveness of non-invasive vagus nerve stimulation (nVNS) in accelerating pilot training. The study, conducted at Wright-Patterson Air Force Base, involved 28 participants from the 711th Human Performance Squadron.

Key findings include:

• Significant positive effect of nVNS over sham on day one (37% after trial one, increasing to 51% after trial 12)
• 99% probability that active nVNS was superior to sham on trial 12
• Higher learning rate in the active nVNS group

The research suggests that electroCore's TAC-STIM (nVNS) technology could potentially enhance sensorimotor learning in USAF Simulator Based Pilot Training, marking a significant advancement in military training techniques.

electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has announced its participation in the 26th Annual H.C. Wainwright Global Investment Conference in New York City from September 9-11, 2024. The company's CEO, Dan Goldberger, will take part in a fireside chat on Wednesday, September 11th, at 12:00 PM ET.

This event provides an opportunity for investors to gain insights into electroCore's operations and future plans. Mr. Goldberger will also be available for one-on-one meetings on the same day, offering a chance for more in-depth discussions with interested parties. The conference serves as a platform for electroCore to showcase its advancements in the field of bioelectronic medicine and wellness to a global investment audience.

Ecora Resources PLC (LSE/TSX:ECOR) announced its half-year results for the six months ended 30 June 2024. Total portfolio contribution increased by 15% year-on-year to $51.3 million, driven by strong performance from the Kestrel steelmaking coal royalty. Adjusted earnings per share rose to 10.38c, up from 9.06c in H1 2023. The company reported a profit before tax of $17.9 million, compared to a loss of $10.2 million in the same period last year.

Ecora declared a half-year dividend of 1.70 cents per share, representing 33% of free cash flow. The company also amended and extended its $150 million revolving credit facility on more favorable terms. Post-period, Ecora acquired a 0.85% Gross Revenue Royalty over the Phalaborwa rare earths project for $8.5 million. However, BHP's decision to temporarily suspend construction of the West Musgrave nickel-copper project was noted as disappointing.

electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has announced its participation in two upcoming investor conferences. CEO Dan Goldberger will attend the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference from August 12-13, 2024. Interested parties can contact Needham to schedule one-on-one meetings.

Additionally, CFO Brian Posner will be present at the 44th Annual Canaccord Genuity Growth Conference at the InterContinental Hotel in Boston, MA. electroCore will host investor meetings on August 13, 2024. To arrange a meeting, interested parties should contact Canaccord Genuity.

These conferences provide electroCore with opportunities to engage with investors and showcase their commercial-stage bioelectronic medicine and wellness solutions.